Hodgkin’s Lymphoma Market

SKU: DMPH2084 | Last Updated On: Nov 08 2022 | Available Formats

>Hodgkin’s Lymphoma Market Expected to reach at a high CAGR 12.8% by 2029:

Hodgkin’s Lymphoma Market is segmented By Therapy (Targeted Therapy, Chemotherapy, Immunotherapy, Others), By Type (Nodular sclerosis Hodgkin lymphoma, Mixed cellularity Hodgkin lymphoma, Lymphocyte-rich Hodgkin lymphoma, Lymphocyte-depleted Hodgkin lymphoma), By Distribution channel (Hospitals, Clinics, Cancer centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

Hodgkin’s Lymphoma Market is expected to grow at a high CAGR 12.8% during the forecasting period (2022-2029).

Hodgkin’s Lymphoma Market



Market CAGR


Segments Covered

By Therapy, By Type, By Distribution channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into the market, Get Our Sample Brochure  

Hodgkin's Lymphoma is a lymphoid malignancy of B-cell origin classified into nodular lymphocyte-predominant Hodgkin's Lymphoma (NLPHL) and classical Hodgkin's Lymphoma (cHL). Hodgkin's Lymphoma accounts for 15% of all cancers in young adults globally, out of which cHL accounts for 95% of all HLs.

Market Dynamics

The major driving forces are the rising prevalence of diabetes, increasing awareness related to needlestick injuries, diabetes monitoring and therapeutics for better disease management, the surge in the adoption of connected medical devices, and increasing R&D activities.

The rising incidence and mortality rates are expected to drive the market growth     

The rising incidence of Hodgkin's Lymphoma is one of the dominating factors propelling the global Hodgkin's lymphoma market. As per cancer.net in 2020,  an estimated 8,540 people (4,570 men and 3,970 women) in the United States will be diagnosed with Hodgkin lymphoma. The number of people diagnosed with this disease dropped by 1.4 % each year. Worldwide, an estimated 83,087 people were diagnosed with Hodgkin lymphoma in 2020.

Children and adults are both affected by Hodgkin lymphoma. It is most prevalent in two age groups in the US. People in their early adult years, especially those in their 20s, make up the first group. People over 55 make up the second category. 39 is the typical diagnostic age. The disease is uncommon in children under the age of 5, but it is the most frequently diagnosed malignancy among teenagers between the ages of 15 and 19. The disease is to blame for 11% of all cancer cases in this age bracket. It's crucial to remember that estimates of Hodgkin lymphoma patient survival rates exist. The estimate is based on annual data on the number of Americans who have this cancer. Thus, these factors are driving the growth of the market in the forecast period.

The availability of alternatives to insulin pens will hamper the growth of the market  

However, the high cost of chemotherapy and the onset of adverse effects of the treatment are expected to hamper the market. For instance, adverse effects like cardiovascular disease and secondary malignancies such as acute leukemia, lymphoma, and solid tumors are likely to occur.

Segment Analysis

The immunotherapy segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)  

Immunotherapy is expected to grow at a significant rate over the period of forecast, owing to increased approvals, and increasing research and development activities. Immunotherapy drugs can be used as a first-line treatment for Hodgkin lymphoma, or they can be used in combination with other treatments, like chemotherapy. Classic Hodgkin lymphoma (cHL) cells usually have the CD30 molecule on their surface. Brentuximab vedotin is an anti-CD30 antibody attached to a chemo drug. The antibody acts like a homing signal, bringing the chemo drug to the lymphoma cells with CD30 on them. The drug enters the cells and kills them when they try to divide into new cells.

In 2020, Northwestern University published results on immunotherapy, A brief course of immunotherapy resulted in complete and near complete remission in nearly two-thirds of previously untreated patients with classical Hodgkin lymphoma. More than 35 percent of patients experienced complete disappearance of lymphoma with pembrolizumab, an immune checkpoint inhibitor. Using this drug as a first-line treatment could reduce the number of patients who later require more intensive chemotherapy or consolidation with radiotherapy,

Geographical Analysis

North America region holds the largest market share of the global Hodgkin’s lymphoma market

North America dominated the global Hodgkin lymphoma market. This is due to the increasing incidence, rising prevalence, and mortality rate of Hodgkin's Lymphoma region reimbursement schemes.  In 2020, an estimated 8,540 people (4,570 men and 3,970 women) in the United States will be diagnosed with Hodgkin lymphoma. From 2009 to 2018, the number of people diagnosed with this disease dropped by 1.4 % each year. Hodgkin lymphoma is more prevalent in females than in males. People are most frequently diagnosed between the ages of 15 and 35, but younger children and older adults may be diagnosed as well. The presence of research and development activities in the region is expected to boost the market in the region.

Competitive Landscape

The Hodgkin’s Lymphoma market is a moderately competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market are Seattle Genetics, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Company, Merck & Co., Inc. F Hoffmann-La Roche, Actinium Pharmaceuticals, Aeterna Zentaris Inc., Affimed Therapeutics Ag, Hospira Inc., Incyte Corporation among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Hodgkin’s lymphoma market globally. For instance, In June 2021, the U.S. Food and Drug Administration received a supplemental new drug Type (sNDA) from Bayer, the firm said in an announcement (FDA). The company has also submitted a marketing authorization Type (MAA) to the European Medicines Agency (EMA) for the combination of copanlisib and rituximab cancer therapy in the United States.

Eli Lilly


A manufacturer of pharmaceuticals is Eli Lilly and Company. The business is involved in the global research, development, production, marketing, and sales of pharmaceutical goods. Basim, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity are among the company's diabetes-related drugs.     

Product Portfolio:

TYVYT (sintilimab injection): Innovent and Lilly in China collaborated to develop the novel medication TYVYT (sintilimab injectable), which meets international quality standards. The NMPA has approved the use of TYVYT to treat classic Hodgkin's lymphoma that has relapsed or become resistant to at least two lines of systemic chemotherapy..

The global Hodgkin’s lymphoma market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.  

Frequently Asked Questions

What is the Projected CAGR value of the Hodgkin’s Lymphoma Market?

Hodgkin’s Lymphoma Market is expected to grow at a CAGR of 2.8% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Hodgkin’s Lymphoma Market during 2022-2029

Which is the fastest growing region in the Hodgkin’s Lymphoma Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Trending Topics

T-cell-lymphoma Market

Mantle Cell Lymphoma Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!